Corazon (Corsee) D. Sanders
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
RARE FDA approves Fayuvi, triggers $203M voucher sale. Ultragenyx Pharmaceutical received FDA approval for its gene therapy Fayuvi. The approval was followed by a second sale of a priority review voucher, bringing in about $203 million within a week. The cash from the voucher sale adds to the company’s resources as it looks to expand its approved product portfolio. Analysts are evaluating whether the newly approved product can support the next growth phase.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
BeOne Medicines Receives Rating Upgrade and Added to Top-Rated List. BeOne Medicines Ltd. has been upgraded to a top rating by analysts. It was also added to a list of top-rated stocks for the week. The upgrade follows recent earnings and infrastructure updates discussed in a broader market analysis. The move may influence investor perception of the company.
Transaction History
| LEGN | ▼ Sell | Open Market | 27,370 | $259K | 9/29/2026 | View on chart |
| LEGN | ▲ Buy | Grant | 20,986 | $0 | 9/24/2026 | View on chart |
| RARE | ▼ Sell | Open Market | 2,000 | $50K | 6/15/2026 | View on chart |
| ONC | ▼ Sell | Open Market | 212 | $66K | 5/22/2026 | View on chart |
| RARE | ▲ Buy | Grant | 7,751 | $0 | 5/14/2026 | View on chart |
| ONC | ▼ Sell | Open Market | 804 | $275K | 11/26/2025 | View on chart |
| ONC | ▲ Buy | Option Exercise | 2,627 | $418K | 11/26/2025 | View on chart |
| ONC | ▼ Sell | Open Market | 1,823 | $620K | 11/26/2025 | View on chart |
| ONC | ▲ Buy | Option Exercise | 2,665 | $415K | 9/5/2025 | View on chart |
| ONC | ▼ Sell | Open Market | 2,665 | $898K | 9/5/2025 | View on chart |
| RARE | ▼ Sell | Open Market | 2,405 | $90K | 6/20/2025 | View on chart |
| ONC | ▲ Buy | Grant | 10,985 | $0 | 5/21/2025 | View on chart |
| RARE | ▲ Buy | Grant | 5,740 | $0 | 5/15/2025 | View on chart |
| RARE | ▼ Sell | Open Market | 584 | $24K | 7/2/2024 | View on chart |
| RARE | ▲ Buy | Grant | 5,345 | $0 | 6/18/2024 | View on chart |
| RARE | ▼ Sell | Open Market | 1,737 | $71K | 6/10/2024 | View on chart |
| ONC | ▲ Buy | Grant | 16,341 | $0 | 6/5/2024 | View on chart |
| RARE | ▼ Sell | Open Market | 585 | $27K | 6/30/2023 | View on chart |
| ONC | ▼ Sell | Open Market | 100 | $18K | 6/23/2023 | View on chart |
| ONC | ▼ Sell | Open Market | 478 | $87K | 6/23/2023 | View on chart |
| ONC | ▲ Buy | Grant | 12,922 | $0 | 6/15/2023 | View on chart |
| RARE | ▼ Sell | Open Market | 1,485 | $77K | 6/8/2023 | View on chart |
| RARE | ▲ Buy | Grant | 3,860 | $0 | 6/7/2023 | View on chart |
| RARE | ▲ Buy | Grant | 3,300 | $0 | 6/24/2022 | View on chart |
| ONC | ▲ Buy | Grant | 16,692 | $0 | 6/22/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 11, 2026
Legend Biotech Faces Revised Valuation After CARVYKTI Data
Legend Biotech’s valuation is under review after the release of five‑year CARVYKTI data. JP Morgan and RBC Capital both lowered their price targets to $33 and $56 respectively, signaling a more cautious outlook. The stock is near its 52‑week low and currently tests support at $18.75, adding pressure to the revised targets.
Legend Biotech Faces Revised Valuation After CARVYKTI Data. Legend Biotech’s valuation is under review after the release of five‑year CARVYKTI data. JP Morgan and RBC Capital both lowered their price targets to $33 and $56 respectively, signaling a more cautious outlook. The stock is near its 52‑week low and currently tests support at $18.75, adding pressure to the revised targets.